New insider activity at Emergent Biosolutions ( (EBS) ) has taken place on March 13, 2025.
In recent transactions involving Emergent Biosolutions stock, Director Neal Franklin Fowler sold 35,000 shares, amounting to a total of $204,050. Additionally, Director Kathryn C Zoon sold 10,000 shares, with the sale valued at $57,300.
Recent Updates on EBS stock
Emergent BioSolutions has experienced significant stock price declines, dropping by 24.6% and 16.0% in recent trading sessions. The company’s Q4 earnings report highlighted both achievements and challenges, including a substantial reduction in net debt by $156 million and improved profitability with a 518% increase in adjusted EBITDA. However, revenue pressures from declining NARCAN sales and conservative future guidance have contributed to a cautious outlook. The company has projected 2025 revenues between $750 million and $850 million, reflecting anticipated challenges in governmental procurement and divestitures. Despite maintaining a strong market share in the naloxone nasal spray market, pricing pressures have impacted revenue. Emergent BioSolutions’ strategic focus on financial stability and market leadership in the biodefense segment, evidenced by $550 million in contract awards, positions it for future growth, albeit with a conservative revenue forecast.
More about Emergent Biosolutions
YTD Price Performance: -46.15%
Average Trading Volume: 1,192,859
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $300.5M